A novel light-activatable payload for targeted oncology conjugates.
GenLumina is developing a preclinical intracellular oncology payload platform that combines partner-selected molecular tumor targeting with an independent second layer of selectivity: controlled spatial light activation.
Two layers of selectivity. One controllable payload.
Molecular targeting determines where the therapeutic construct goes. GenLumina adds an independent switch that determines where intracellular cytotoxic activity is activated.
Novartis-selected targeting
An antibody, peptide or other targeting ligand selected around Novartis biology directs the construct toward the intended tumor cells.
Intracellular delivery
The ultra-small DNA-silver nanocluster payload is delivered into target cells and localizes intracellularly.
Spatial activation
Controlled local light activates the payload within the selected treatment field.
Selective killing
Activation triggers localized cytotoxic activity within the illuminated treatment volume.
Target biology determines where the payload goes. Light determines where it becomes active.
Platform proof established. Partner-specific validation is next.
GenLumina has demonstrated targeted and conjugated in-vitro activity in breast and colorectal cancer models. The next value step is to evaluate the payload with targeting biology selected by a pharmaceutical partner.
Demonstrated
- Light-activated intracellular cytotoxic payload concept
- Targeted / conjugated in-vitro proof-of-concept
- Activity in breast cancer models
- Activity in colorectal cancer models
- Antibody- and peptide-targeted internal starting points
Novartis-specific validation
- Select one Novartis antibody, peptide or ligand
- Define the conjugation strategy and assess stability
- Measure cellular uptake and intracellular localization
- Evaluate controlled light activation and tumor-cell killing
- Assess selectivity and therapeutic-window parameters
- Progress to in-vivo proof-of-concept if predefined criteria are met
A potential fit with targeted delivery and next-generation oncology payload innovation.
This section is deliberately partner-specific. The scientific and commercial collaboration structure remains the same GenLumina platform model used across partner programmes.
Novartis publicly lists breast, colorectal, pancreatic, prostate and lung cancers among oncology partnering areas, creating multiple potential settings in which the platform hypothesis could eventually be evaluated.
Novartis publicly identifies targeted delivery, selective tropism, biodistribution and intracellular trafficking within its biotherapeutics partnering interests.
Novartis' publicly announced Myricx Bio transaction reflects strategic interest in next-generation targeted drug conjugates and differentiated payload innovation.
Start with one focused scientific question.
The initial objective is not a broad platform licence. It is to determine whether GenLumina's payload architecture merits further development with one Novartis-selected targeting molecule.
Can a Novartis-selected tumor-targeting antibody, peptide or ligand be combined with the GenLumina payload to create a differentiated therapeutic architecture with independent spatial activation?
Suggested work package
- Define the Novartis-selected targeting molecule and conjugation strategy
- Assess conjugation feasibility, stability and reproducibility
- Measure cellular uptake and intracellular localization
- Evaluate controlled light activation, tumor-cell killing and selectivity
- Progress to in-vivo proof-of-concept if predefined criteria are met
Validate first. Create the option to license.
The parties can define the scientific decision criteria first and separately agree how successful validation could create an option to advance toward programme-specific commercial rights. No broad platform transfer is required.
Novartis targeting biology
Select one antibody, peptide or ligand around a relevant Novartis oncology programme.
Partner-specific PoC
Test the combination against jointly agreed technical and biological decision criteria.
Decide whether to advance
If the PoC succeeds, Novartis can progress an agreed option toward broader programme development rights.
Programme-specific rights
Commercial rights can then be negotiated for a defined programme, indication and geographic territory while GenLumina retains ownership of the underlying platform.
The intended model allows programme-specific commercial rights while preserving GenLumina's ability to develop the core payload technology and work with additional targets, indications and pharmaceutical partners.
Which Novartis targeting molecule should we test first?
We would welcome an initial non-confidential scientific discussion to select one targeting molecule, define the feasibility package and agree which evidence should determine whether a successful programme advances.